|Bid||0.000 x 3100|
|Ask||0.000 x 3100|
|Day's Range||0.080 - 0.100|
|52 Week Range||0.070 - 2.970|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on ANTH sign up now at www.wallstequities.com/registration. The nature of the operations of firms in the Biotech industry makes equities in this space more suited to aggressive, risk-tolerant investors.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 27) Aptinyx Inc (NASDAQ: APTX ) Cardiovascular Systems Inc (NASDAQ: ...
Today, Anthera Pharmaceuticals (ANTH) registered a stock price decline of ~53% on news that the stock will be suspended from trading on the NASDAQ Capital Market at the start of business tomorrow. Following the delisting, Anthera Pharmaceuticals’ securities will be listed on the OTC Market. If the company requires its stock to trade on another trading platform, it may take the necessary steps.
Anthera Pharmaceuticals, Inc. (ANTH) (“Anthera” or the “Company”) announced today that it has withdrawn its request for a hearing to appeal the delisting determination of the Staff of the Nasdaq Stock Market (“Nasdaq”) from the Nasdaq Capital Market. The Nasdaq Staff has accepted the Company’s withdrawal and will suspend the trading of the Company’s securities at the open of business on June 28, 2018.
If you are a shareholder in Anthera Pharmaceuticals Inc’s (NASDAQ:ANTH), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
In this article, I will take a quick look at Anthera Pharmaceuticals Inc’s (NASDAQ:ANTH) recent ownership structure – an unconventional investing subject, but an important one. Ownership structure of aRead More...
Stock Research Monitor: AMPE, ANTH, and ARLZ LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . In today's pre-market ...
Anthera Pharmaceuticals Inc’s (NASDAQ:ANTH) latest earnings update in December 2017 confirmed that losses became smaller relative to the prrior year’s level – great news for investors Below is a briefRead More...
Anthera Pharmaceuticals Inc’s (NASDAQ:ANTH): Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The US$7.44M market-cap company announced aRead More...
Understanding Anthera Pharmaceuticals Inc’s (NASDAQ:ANTH) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
Anthera Pharmaceuticals Inc., which hung its hopes on a two-time loser treatment for cystic fibrosis patients, said the drug failed in a late-stage trial. Anthera President and CEO Craig Thompson said in a statement that the company was "greatly disappointed" by the results of the study. Anthera was positioning the drug as significant for patients with cystic fibrosis and other conditions, such as pancreatitis, whose pancreas can't produce three critical enzymes that move into the small intestine to help people carry out normal digestion.
Cystic fibrosis patients were hopeful that the drug could reduce their pill burden; instead a late-stage clinical trial failure caused Anthera Pharmaceutical's stock to dip as low as 40 cents per share.
High-growth stocks that are financially stable are attractive for many reasons. They provide a strong upside to your portfolio, with less likelihood of downside risks compared to less financially robustRead More...